IRD
NASDAQ · Biotechnology
Opus Genetics Inc
$4.06
-0.25 (-5.80%)
Financial Highlights (FY 2026)
Revenue
21.62M
Net Income
-75,515,598
Gross Margin
87.5%
Profit Margin
-349.3%
Rev Growth
-29.1%
D/E Ratio
0.07
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 87.5% | 87.5% | 47.3% | 47.3% |
| Operating Margin | -271.9% | -244.7% | -3.5% | -3.0% |
| Profit Margin | -349.3% | -331.9% | -4.0% | -3.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 21.62M | 30.50M | 29.63M | 31.10M |
| Gross Profit | 18.92M | 26.69M | 14.01M | 14.71M |
| Operating Income | -58,789,962 | -74,638,123 | -1,023,494 | -939,153 |
| Net Income | -75,515,598 | -95,872,532 | -1,185,756 | -1,130,465 |
| Gross Margin | 87.5% | 87.5% | 47.3% | 47.3% |
| Operating Margin | -271.9% | -244.7% | -3.5% | -3.0% |
| Profit Margin | -349.3% | -331.9% | -4.0% | -3.6% |
| Rev Growth | -29.1% | -29.1% | +20.7% | -3.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 13.19M | 13.19M | 78.04M | 72.81M |
| Total Equity | 179.16M | 179.16M | 103.70M | 96.68M |
| D/E Ratio | 0.07 | 0.07 | 0.75 | 0.75 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -58,697,507 | -78,660,786 | -1,569,658 | -1,729,159 |
| Free Cash Flow | — | — | -1,455,645 | -1,245,008 |